SynCardia Plans U.S. Equivalency Trial Of Portable Total Artificial Heart
This article was originally published in The Gray Sheet
Executive Summary
SynCardia's CardioWest Total Artificial Heart could be used in up to 500 U.S. cardiac transplant candidates annually, according to the firm
You may also be interested in...
Syncardia TAH
Syncardia takes step toward more mobile CardioWest Total Artificial Heart through license of small, lightweight driver from MEDOS medizintechnik AG in Stolberg, Germany, announced Sept. 8. Syncardia currently is planning an IDE for a more portable TAH to follow PMA approval of the first-generation device - expected later this year - and has discussed development of a TAH that fits in a backpack (1"The Gray Sheet" Feb. 23, 2004, p. 20)...
Syncardia TAH
Syncardia takes step toward more mobile CardioWest Total Artificial Heart through license of small, lightweight driver from MEDOS medizintechnik AG in Stolberg, Germany, announced Sept. 8. Syncardia currently is planning an IDE for a more portable TAH to follow PMA approval of the first-generation device - expected later this year - and has discussed development of a TAH that fits in a backpack (1"The Gray Sheet" Feb. 23, 2004, p. 20)...
Heart Failure Patient Conversion From LVAD To TAH Debated By Panel
FDA's Circulatory System Devices Panel has left the door open for cardiac surgeons to use SynCardia's CardioWest Total Artificial Heart (TAH) in transplant candidates who fail left ventricular assist device (LVAD) therapy